Bunting Peter S
Department of Pathology and Laboratory Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, K1Y 4E9, Canada.
Clin Biochem. 2004 Oct;37(10):898-903. doi: 10.1016/j.clinbiochem.2004.05.023.
To determine whether there has been a change in the rate of screening in Ontario in 2002 compared to 1995.
A questionnaire was mailed to 520 physicians, associated with PSA records selected randomly from the database of a large community laboratory. Physicians were asked to consult their records as to the reasons for PSA testing.
There were 285 usable responses from 520 mailings (response rate 55%), mostly (91%) from family or general practice. Reasons for testing, expressed as proportions of responses, were as follows (this study, 1995 study and P value for the differences): screening for prostate cancer (74%, 63%; P = 0.059), diagnosis of urinary symptoms (30%, 40%; P = 0.027), follow-up of a medical procedure or drug therapy (14%, 32%; P = 0.001), confirmation of a previous PSA result (14%, 6%; P = 0.015) and other reasons (7%, 8%; P = 0.73). Of those records with screening as one reason for testing, 80% vs. 66% (P = 0.003) indicated it was the only reason; 86% vs. 73% (P = 0.003) indicated that it was part of a routine examination, and 54% vs. 64% (P = 0.052) indicated that the test was requested by the patient.
These findings are consistent with increased screening for prostate cancer with PSA.
确定安大略省2002年与1995年相比筛查率是否发生了变化。
向520名医生邮寄了一份问卷,这些医生与从一个大型社区实验室数据库中随机选取的前列腺特异性抗原(PSA)记录相关。要求医生查阅他们的记录以了解PSA检测的原因。
520份邮件中有285份可用回复(回复率55%),大部分(91%)来自家庭医生或全科医生。检测原因以回复比例表示如下(本研究、1995年研究以及差异的P值):前列腺癌筛查(74%,63%;P = 0.059)、泌尿系统症状诊断(30%,40%;P = 0.027)、医疗程序或药物治疗的随访(14%,32%;P = 0.001)、先前PSA结果的确认(14%,6%;P = 0.015)以及其他原因(7%,8%;P = 0.73)。在那些将筛查作为检测原因之一的记录中,80%对66%(P = 0.003)表明这是唯一原因;86%对73%(P = 0.003)表明这是常规检查的一部分,54%对64%(P = 0.052)表明该检测是患者要求的。
这些发现与使用PSA对前列腺癌进行更多筛查是一致的。